Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vasopressin for Social Deficits in Children With Autism
NCT01962870Phase 2Completed
- Sponsor
- Stanford University
- Start
- Dec 2013
- Primary completion
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Vasopressin with Placebo (2 arms). Primary endpoint: Social Responsiveness Scale, 2nd Edition at 4 weeks. Started Dec 2013; status: completed.
02
Drugs
vasopressin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01962870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962870.